Protalix BioTherapeutics, Inc.’s $54.1 Million private notes exchange agreement, and a $22.5 Million private placement of the company’s Secured Convertible Notes

Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 Million private notes exchange agreement, and a $22.5 Million private...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here